Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries

Mathers, 2006, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med, 3, e442, 10.1371/journal.pmed.0030442 Antiretroviral Therapy Cohort Collaboration, 2010, Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies, Clin Infect Dis, 50, 1387, 10.1086/652283 Palella, 2006, Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study, J Acquir Immune Defic Syndr, 43, 27, 10.1097/01.qai.0000233310.90484.16 Barbaro, 2002, Cardiovascular manifestations of HIV infection, Circulation, 106, 1420, 10.1161/01.CIR.0000031704.78200.59 Mocroft, 2010, Serious fatal and nonfatal non-AIDS-defining illnesses in Europe, J Acquir Immune Defic Syndr, 55, 262, 10.1097/QAI.0b013e3181e9be6b Sudano, 2006, Cardiovascular disease in HIV infection, Am Heart J, 151, 1147, 10.1016/j.ahj.2005.07.030 Morlat, 2014, Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000, AIDS, 28, 1181, 10.1097/QAD.0000000000000222 Weber, 2013, Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study, HIV Med, 14, 195, 10.1111/j.1468-1293.2012.01051.x Triant, 2007, Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease, J Clin Endocrinol Metab, 92, 2506, 10.1210/jc.2006-2190 Durand, 2011, Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database, J Acquir Immune Defic Syndr, 57, 245, 10.1097/QAI.0b013e31821d33a5 Freiberg, 2013, HIV infection and the risk of acute myocardial infarction, JAMA Intern Med, 173, 614, 10.1001/jamainternmed.2013.3728 Lang, 2010, Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, 24, 1228, 10.1097/QAD.0b013e328339192f Choi, 2010, Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons, Circulation, 121, 651, 10.1161/CIRCULATIONAHA.109.898585 Currier, 2003, Coronary heart disease in HIV-infected individuals, J Acquir Immune Defic Syndr, 33, 506, 10.1097/00126334-200308010-00012 Friis-Moller, 2003, Combination antiretroviral therapy and the risk of myocardial infarction, N Engl J Med, 349, 1993, 10.1056/NEJMoa030218 Petoumenos, 2014, Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D/A/D CVD risk equation and general population CVD risk equations, HIV Med, 15, 595 Kaplan, 2007, Ten-year predicted coronary heart disease risk in HIV-infected men and women, Clin Infect Dis, 45, 1074, 10.1086/521935 Saves, 2003, Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population, Clin Infect Dis, 37, 292, 10.1086/375844 Bergersen, 2004, Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects, Eur J Clin Microbiol Infect Dis, 23, 625, 10.1007/s10096-004-1177-6 Neumann, 2004, Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients – part III: age differences, Eur J Med Res, 9, 267 Hadigan, 2003, Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution, Clin Infect Dis, 36, 909, 10.1086/368185 Knobel, 2007, Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM), AIDS Patient Care STDS, 21, 452, 10.1089/apc.2006.0165 Glass, 2006, Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study, HIV Med, 7, 404, 10.1111/j.1468-1293.2006.00400.x Matetzky, 2003, Acute myocardial infarction in human immunodeficiency virus-infected patients, Arch Intern Med, 163, 457, 10.1001/archinte.163.4.457 Hsue, 2004, Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection, Circulation, 109, 316, 10.1161/01.CIR.0000114520.38748.AA Boccara, 2011, Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis, Eur Heart J, 32, 41, 10.1093/eurheartj/ehq372 Perello, 2011, Clinical presentation of acute coronary syndrome in HIV-infected adults: a retrospective analysis of a prospectively collected cohort, Eur J Intern Med, 22, 485, 10.1016/j.ejim.2011.02.017 Pearce, 2012, Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive versus sero-negative individuals, Am J Cardiol, 110, 1078, 10.1016/j.amjcard.2012.05.045 Lorgis, 2013, Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database, Circulation, 127, 1767, 10.1161/CIRCULATIONAHA.113.001874 Tseng, 2012, Sudden cardiac death in patients with human immunodeficiency virus infection, J Am Coll Cardiol, 59, 1891, 10.1016/j.jacc.2012.02.024 Worm, 2012, Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke, J Infect Dis, 205, 535, 10.1093/infdis/jir788 Behrens, 1998, Vascular complications associated with use of HIV protease inhibitors, Lancet, 351, 1958, 10.1016/S0140-6736(98)26026-0 Gallet, 1998, Vascular complications associated with use of HIV protease inhibitors, Lancet, 351, 1958, 10.1016/S0140-6736(05)78643-8 Henry, 1998, Severe premature coronary artery disease with protease inhibitors, Lancet, 351, 1328, 10.1016/S0140-6736(05)79053-X Vittecoq, 1998, Vascular complications associated with use of HIV protease inhibitors, Lancet, 351, 1959, 10.1016/S0140-6736(05)78644-X Jutte, 1999, Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?, AIDS, 13, 1796, 10.1097/00002030-199909100-00034 Rickerts, 2000, Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study, Eur J Med Res, 5, 329 David, 2002, Ischemic cardiovascular disease in persons with human immunodeficiency virus infection, Clin Infect Dis, 34, 98, 10.1086/324745 Holmberg, 2002, Protease inhibitors and cardiovascular outcomes in patients with HIV-1, Lancet, 360, 1747, 10.1016/S0140-6736(02)11672-2 Bozzette, 2003, Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection, N Engl J Med, 348, 702, 10.1056/NEJMoa022048 Klein, 2002, Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?, J Acquir Immune Defic Syndr, 30, 471, 10.1097/00126334-200208150-00002 Mary-Krause, 2003, Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men, AIDS, 17, 2479, 10.1097/00002030-200311210-00010 d’Arminio, 2004, Cardio- and cerebrovascular events in HIV-infected persons, AIDS, 18, 1811, 10.1097/00002030-200409030-00010 Friis-Moller, 2007, Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, 356, 1723, 10.1056/NEJMoa062744 Obel, 2007, Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study, Clin Infect Dis, 44, 1625, 10.1086/518285 Worm, 2010, Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study, J Infect Dis, 201, 318, 10.1086/649897 Lang, 2010, Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4, Arch Intern Med, 170, 1228, 10.1001/archinternmed.2010.197 Bavinger, 2013, Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review, PLoS One, 8, e59551, 10.1371/journal.pone.0059551 D’Ascenzo, 2012, Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy, Eur Heart J, 33, 875, 10.1093/eurheartj/ehr456 Monforte, 2013, Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events, AIDS, 27, 407, 10.1097/QAD.0b013e32835b2ef1 Lang, 2012, HIV replication and immune status are indeprendent predictore of the risk of myocardial infarction in HIV-Infected individuals, Clin Infect Dis, 55, 600, 10.1093/cid/cis489 Silverberg, 2014, immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care, J Acquir Immune Defic Syndr, 65, 160, 10.1097/QAI.0000000000000009 El-Sadr, 2006, CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, 355, 2283, 10.1056/NEJMoa062360 Crowe, 2010, The macrophage: the intersection between HIV infection and atherosclerosis, J Leukoc Biol, 87, 589, 10.1189/jlb.0809580 Stein, 2001, Use of Human Immunideficiency Virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction, Circulation, 104, 257, 10.1161/01.CIR.104.3.257 Boccara, 2013, HIV and coronary heart disease: time for a better understanding, J Am Coll Cardiol, 61, 511, 10.1016/j.jacc.2012.06.063